Blueprint Medicines (BPMC) reported $71.96 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 85.6$1.82 for the same period compares to -$2.65 a year ago. The reported revenue compares to the Zacks Consensus Estimate of$67.28 million, representing a surprise of +6.95%. The company delivered an EPS surprise of +10.78%, with the consensus EPS estimate being -$2.04. While investors closely watch year-over-year changes in headline numbers -- revenue and ...